Publications Office of the EU
SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS: FLORBETABEN (18F) (NEURACEQ), MERTIATIDA (NEPHROMAG) Y PIFLUFOLASTAT (18F) (PYLCLARI). - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS: FLORBETABEN (18F) (NEURACEQ), MERTIATIDA (NEPHROMAG) Y PIFLUFOLASTAT (18F) (PYLCLARI).

  • Awarded
    30/01/2025
  • Today
    13/02/2025
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Servicio Madrileno de Salud, Hospital Universitario La Paz
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: ES300 Madrid
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
469,149.66 EUR
Tender reference number
Not available
Description

SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS: FLORBETABEN (18F) (NEURACEQ), MERTIATIDA (NEPHROMAG) Y PIFLUFOLASTAT (18F) (PYLCLARI).

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Criterion:
Type: cost
Description: Coste
Weight (percentage, exact): 100
Estimated value
Not available
Final contracted value
469,149.66 EUR
Award of contract
Official name: Curium Pharma Spain, S.A.
Postal address:
Town: Alcobendas
Postal code: 28100
Country:
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.